Clinical Trial Update: Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. [Phase 2]

View source ↗

Summary

This is a Phase 2 exploratory neoadjuvant trial evaluating SHR-A1811 in combination with Pertuzumab for HER2-positive breast cancer; the study status is Not Yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• SHR-A1811

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING